FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC
Evidence for efficacy is based on the results from the RELAY study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
JAVELIN Bladder 100 Demonstrates Significantly Prolonged OS in Advanced Urothelial Cancer
Results of first-line maintenance avelumab plus best supportive care reported at ASCO 2020 Virtual Meeting
Clinical Characteristics and Risk Factors for COVID-19 Severity and Mortality Among Cancer Patients in Wuhan and Hubei
Findings from two Chinese multicentre, retrospective, cohort studies
EMA Recommends Granting a Marketing Authorisation for Biosimilar Trastuzumab
FDA Approves Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Evidence for efficacy is based on the results from the IMbrave150 study
EMA Recommends Granting a Conditional Marketing Authorisation for Entrectinib
It is intended for the treatment of patients whose solid tumours have NTRK gene fusion or for patients with ROS1-positive advanced NSCLC
COVID-19 Mortality in UK Patients with Cancer on Anticancer Treatments Described
Results of the UK Coronavirus Cancer Monitoring Project
Pembrolizumab for Leptomeningeal Carcinomatosis
Results from a phase II trial
EMA Recommends Extension of Indications for Olaparib
New indication concerns maintenance treatment of metastatic adenocarcinoma of the pancreas with germline BRCA1/2-mutations
EMA Recommends Granting a Marketing Authorisation for Alpelisib
Alpelisib is intended for the treatment of advanced breast cancer with a PIK3CA mutation
FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
Evidence for efficacy is based on the results from the CHECKMATE-9LA study
FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC
FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic